N/A
Manufactured by ANI Pharmaceuticals, Inc.
30 FDA adverse event reports analyzed
Last updated: 2026-04-15
LIDOCAINE HYDROCHLORIDE, MENTHOL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for LIDOCAINE HYDROCHLORIDE, MENTHOL include ABDOMINAL PAIN UPPER, BLOOD CHOLESTEROL INCREASED, CONSTIPATION, COVID-19 PNEUMONIA, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LIDOCAINE HYDROCHLORIDE, MENTHOL.
Out of 3 classified reports for LIDOCAINE HYDROCHLORIDE, MENTHOL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 30 FDA FAERS reports that mention LIDOCAINE HYDROCHLORIDE, MENTHOL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ABDOMINAL PAIN UPPER, BLOOD CHOLESTEROL INCREASED, CONSTIPATION, COVID-19 PNEUMONIA, DIARRHOEA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with LIDOCAINE HYDROCHLORIDE, MENTHOL. Always verify the specific product and NDC with your pharmacist.